This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== mEos2 === mEosFP is another monomeric Eos variant that folds effectively at 37 degrees Celsius. Where tdEos (tandem dimer) cannot fuse to targets such as histones, tubulin, intermediate filaments and gap junctions, and mEos (monomeric) which can only be used successfully at 30 degrees Celsius, mEos2 is an engineered variant that can fold effectively at 37 degrees Celsius and successfully label targets intolerant to fusion from other fluorescent protein dimers . mEos2 shows almost identical spectral properties, brightness, pKa, photoconversion, contrast and maturation properties to WT Eos. The localization precision of mEos2 is twice as great as other monomeric fluorescent proteins.
== Sources == Bingham, Jonathan Brewster (1953). Shirt-Sleeve Diplomacy: Point 4 in Action. John Day & Co. Brown, William Adams Jr.; Opie, Redvers (1953). American Foreign Assistance. Washington, DC: The Brookings Institution. Butterfield, Samuel Hale (2004). U.S. Development Aid – An Historic First: Achievements and Failures in the Twentieth Century. Westport, CN: Praeger. ISBN 0-313-31910-3. Glick, Philip M. (1957). The Administration of Technical Assistance: Growth in the Americas. Chicago: University of Chicago Press. Haviland, H. Field (1958). "Foreign Aid and the Policy Process: 1957". The American Political Science Review. 52 (3): 689–724. doi:10.2307/1951900. JSTOR 1951900. S2CID 144564474. Hayes, Samuel J., ed. (1971). The Beginnings of American Aid to Southeast Asia: The Griffin Mission of 1950. Lexington, MA: Heath Lexington Books. Jolly, Richard; Emmerji, Louis; Ghai, Dharam; Lapeyre, Frederic (2004). UN Contributions to Development Thinking and Practice. Bloomington: Indiana University Press. Kaufman, B. Ira (1982). Trade and aid : Eisenhower's foreign economic policy, 1953–1961. Baltimore, MD: Johns Hopkins University Press. p. 82. ISBN 978-0-8018-2623-8. Nowels, Larry Q. (February 1987). Economic Security Assistance As a Tool of American Foreign Policy: The Current Dilemma and Future Options (PDF) (Report). National War College. Archived from the original (PDF) on 2017-10-11. Retrieved 2017-06-20 – via Development Experience Clearinghouse. Ruttan, Vernon W. (1996). United States Development Assistance Policy: The Domestic Politics of Foreign Economic Aid.
Penicillin-binding proteins (PBP) are a group of proteins that are characterized by their affinity for and binding of penicillin. They are a normal constituent of many bacteria; the name just reflects the way by which the protein was discovered. All β-lactam antibiotics (except for tabtoxinine-β-lactam, which inhibits glutamine synthetase) bind to PBPs, which are essential for bacterial cell wall synthesis. PBPs are members of a subgroup of transpeptidase enzymes called DD-transpeptidases.
==== Separatory funnels ==== Separatory funnels, colloquially called a "sep funnel," are commonly used for small-scale extractions in research or teaching labs. To perform an extraction, two immiscible liquids, typically an aqeuous solution and an organic solvent, are added to the sep funnel. The sep funnel is then shaken using appropriate technique to increase the area of contact between the two phases to aid extraction. After the two layers are allowed to settle and separate, each layer is drained from the bottom of the sep funnel into separate containers. Multiple extractions may be performed on the same reaction mixture to increase product recovery. After extraction, the extract phase can be used for further processing Partitioning of organic compounds between the organic and aqueous phases can be controlled by adjusting the pH of the aqeuous phase. For example, increasing the pH of the aqueous solution will deprotanate organic acids, giving them a negative charge that favors partitioning into polar solvents like water. Adding a strong acid to decrease pH can have the opposite effect, neutralizing conjugate bases to form neutral compounds that can partition more easily into the organic phase. This technique can be used in teaching labs to extract compounds like caffeine from coffee or tea using ethyl acetate as the organic extractant.
Delta atracotoxin (δ-ACTX-Ar1, robustoxin, or robustotoxin) is a low-molecular mass neurotoxic polypeptide found in the venom of the Sydney funnel-web spider (Atrax robustus). Delta atracotoxin produces potentially fatal neurotoxic symptoms in primates, by slowing the inactivation of sodium ion channels in autonomic and motor neurons. In the spiders' intended insect prey, the toxin exerts this same activity upon calcium ion channels. The structure of atracotoxin comprises a core beta region with a cystine knot motif, a feature seen in other neurotoxic polypeptides.
Sources: en.wikipedia.org
=== Pharmacokinetics === Orally administered endoxifen is rapidly absorbed and systemically available. The time to peak (Tmax) is between 4.5 and 6 hours after oral administration. It is not metabolized by cytochrome P450 enzymes. The half-life (t½) life of endoxifen is 52.1 to 58.1 hours.
== Mode of action == Cinoxacin mode of action involves the inhibiting of DNA gyrase, a type II topoisomerase, and topoisomerase iv, which is an enzyme necessary to separate replicated DNA, thereby inhibiting cell division.
==== Increase in cancer risk ==== The IARC concluded that if unprocessed red meat does cause cancer, there is a 17% higher risk of colorectal cancer for every 100 g of unprocessed red meat consumed daily. It found an 18% higher risk of colorectal cancer for every 50 g of processed red meat consumed daily. A 2021 umbrella review reported an increase of 11–51% risk of multiple cancer per 100g/d increment of red meat, and an increase of 8–72% risk of multiple cancer per 50g/d increment of processed meat. A 2022 Burden of Proof study analyzed data from epidemiological evidence (not mechanistic evidence) and found that each 100 g of unprocessed red meat consumed per day would increase colorectal cancer risk by at least 6% and breast cancer by at least 3%. The Burden of Proof methodology was later criticized for systematically under-estimating levels of risk.
== Medical uses == Verapamil is used for controlling ventricular rate in supraventricular tachycardia (SVT) and migraine headache prevention. Verapamil is also used for the treatment of angina (chronic stable, vasospastic or Prinzmetal variant), unstable angina (crescendo, preinfarction), and for the prevention of paroxysmal supraventricular tachycardia (PSVT). Verapamil is a class-IV antiarrhythmic and more effective than digoxin in controlling ventricular rate. Verapamil is not listed as a first line antihypertensive agent by the guidelines provided by JAMA in JNC-8. However, it may be used to treat hypertension if patient has co-morbid atrial fibrillation or other types of arrhythmia. Verapamil is used intra-arterially to treat cerebral vasospasm. It is also used to treat cluster headaches. Tentative evidence supports the use of verapamil topically to treat plantar fibromatosis. Use of verapamil in people with recent onset of type 1 diabetes may improve pancreatic beta cell function. In a 2023 meta-analysis involving data from two randomized controlled trials (113 patients with recent onset type-1 diabetes), it was demonstrated that the use of verapamil over one year was associated with significantly higher C-peptide area under the curve levels. Higher C-peptide levels means better pancreatic insulin production and beta cell function. Verapamil has been reported to be effective in both short-term and long-term treatment of mania and hypomania. Addition of magnesium oxide to the verapamil treatment protocol enhances the antimanic effect.
==== Imaging ==== Ultrasound of the thyroid may be used to reveal whether structures are solid or filled with fluid, helping to differentiate between nodules and goitres and cysts. It may also help differentiate between malignant and benign lesions. When further imaging is required, a radiolabelled iodine-123 or technetium-99 uptake scan may take place. This can determine the size and shape of lesions, reveal whether nodules or goitres are metabolically active, and reveal and monitor sites of thyroid disease or cancer deposits outside the thyroid. A fine needle aspiration of a sample of thyroid tissue may be taken in order to evaluate a lesion seen on ultrasound which is then sent for histopathology and cytology. Computed tomography of the thyroid plays an important role in the evaluation of thyroid cancer. CT scans often incidentally find thyroid abnormalities, and thereby practically becomes the first investigation modality.
Sources: en.wikipedia.org
In 1809 the Tyroleans rose up against Bavarian authority and succeeded three times in defeating Bavarian and French troops trying to retake the country. Austria lost the War of the Fifth Coalition against France, and got harsh terms in the Treaty of Schönbrunn in 1809. Glorified as Tyrol's national hero, Andreas Hofer, the leader of the uprising, was executed in 1810 in Mantua. His forces had lost a fourth and final battle against the French and Bavarian forces. In 1810 Bavaria was forced by France to cede southern Tyrol (the Etschkreis plus Bozen) to the Kingdom of Italy, most of which became the Department of Alto Adige, and the eastern part of the Eisackkreis (roughly modern East Tyrol) to the French Empire's Illyrian Provinces. The remainder of the Eisackkreis was transferred to the Innkreis (along with Werdenfels and the newly-acquired Zillertal), while parts of the Innkreis were transferred to other Kreise: the eastern part around St. Johann and Kitzbühel to the Salzachkreis; the Lechtal in the north-west to the Illerkreis. Tyrol remained divided between Bavaria and Napoleonic Italy for another four years.
== GSNOR == The enzyme GSNO reductase (GSNOR) reduces S-nitrosoglutathione (GSNO) to an unstable intermediate, S-hydroxylaminoglutathione, which then rearranges to form glutathione sulfonamide, or in the presence of GSH, forms glutathione disulfide and hydroxylamine.
== Amino-acid propensities == Different amino-acid sequences have different propensities for forming α-helical structure. Alanine, uncharged glutamate, leucine, charged arginine, methionine and charged lysine have especially high helix-forming propensities, whereas proline and glycine have poor helix-forming propensities. Proline either breaks or kinks a helix, both because it cannot donate an amide hydrogen bond (because it has none) and because its sidechain interferes sterically with the backbone of the preceding turn – inside a helix, which forces a bend of about 30° in the helix's axis. However, proline is often the first residue of a helix, presumably due to its structural rigidity. At the other extreme, glycine also tends to disrupt helices because its high conformational flexibility makes it entropically expensive to adopt the relatively constrained α-helical structure.
== Interactions == Pappalysin-1 has been shown to interact with major basic protein. Studies conducted at the Royal London Hospital in the United Kingdom, have shown that a marker of Down syndrome may be expressed during the first trimester and second trimester of a pregnancy term. Concentrations of the Pregnancy-Associated Plasma Protein (PAPPA) gene as well as other markers can help screen for Down syndrome in the beginning stages of a woman's gestational period.
== History == 1930s – first reports of the use of sucrose for gel electrophoresis; moving-boundary electrophoresis (Tiselius) 1950 – introduction of "zone electrophoresis" (Tiselius); paper electrophoresis 1955 – introduction of starch gels, mediocre separation (Smithies) 1959 – introduction of polyacrylamide gels; discontinuous electrophoresis (Ornstein and Davis); accurate control of parameters such as pore size and stability (Raymond and Weintraub) 1965 – introduction of free-flow electrophoresis (Hannig) 1966 – first use of agar gels 1969 – introduction of denaturing agents especially SDS separation of protein subunit (Weber and Osborn) 1970 – Lämmli separated 28 components of T4 phage using a stacking gel and SDS 1972 – agarose gels with ethidium bromide stain 1975 – 2-dimensional gels (O'Farrell); isoelectric focusing, then SDS gel electrophoresis 1977 – DNA sequencing gels (Sanger) 1981 – introduction of capillary electrophoresis (Jorgenson and Lukacs) 1984 – pulsed-field gel electrophoresis enables separation of large DNA molecules (Schwartz and Cantor) 2004 – introduction of a standardized polymerization time for acrylamide solutions to optimize gel properties with preparative native PAGE A 1959 book on electrophoresis by Milan Bier cites references from the 1800s. However, Oliver Smithies made significant contributions. Bier states: "The method of Smithies ... is finding wide application because of its unique separatory power." Taken in context, Bier clearly implies that Smithies' method is an improvement.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.